{"id":390516,"date":"2018-12-20T00:00:00","date_gmt":"2018-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0007-2018-biopharma-type-2-diabetes-unmet-need-us-eu-2018\/"},"modified":"2026-04-30T11:25:03","modified_gmt":"2026-04-30T11:25:03","slug":"unnemd0007-2018-biopharma-type-2-diabetes-unmet-need-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0007-2018-biopharma-type-2-diabetes-unmet-need-us-eu-2018\/","title":{"rendered":"Type 2 Diabetes | Unmet Need | US\/EU | 2018"},"content":{"rendered":"<p>Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a\u00a0high unmet need exists for drugs that can effectively control the progression of this\u00a0prevalent disease. The 2018 Type 2 Diabetes Unmet Need content focuses on leading branded agents and analysis of more available clinical data. Several currently marketed agents have scope to further move up the treatment algorithm. Therefore, understanding physicians\u2019 perception\u00a0of\u00a0these products has become increasingly important. This study reveals which drug attributes drive endocrinologists\u2019 prescribing behavior and explores how current therapies compare across efficacy, safety, and delivery attributes.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>Which drugs offer the greatest ability to reduce HbA1c to target?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which represent hidden opportunities?<\/li>\n<li>What price range and\u00a0clinical attributes of new T2D drugs are\u00a0needed to influence physicians\u2019\u00a0prescribing preference\u00a0over current market players?<\/li>\n<li>How do the leading diabetes brands compare among\u00a0endocrinologists, and\u00a0do\u00a0opinions vary between U.S.\u00a0and European physicians?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Unmet Need provides quantitative insight into U.S. and European physicians\u2019 perception\u00a0of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, and the United Kingdom.<\/p>\n<p><strong>Primary\u00a0research:\u00a0<\/strong>Survey of 61\u00a0U.S. endocrinologists\u00a0and 31\u00a0European endocrinologists.<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Victoza, Trulicity, Invokana, Jardiance, Farxiga\/Forxiga, Januvia, and Onglyza.<\/p>\n<p><strong>Key metrics included:<\/strong><\/p>\n<ul>\n<li>Stated versus derived analysis of U.S. and European physicians\u2019 prescribing behavior.<\/li>\n<li>Conjoint analysis with U.S. and European physicians\u00a0includes market simulator.<\/li>\n<li>Assessment of current therapies\u2019\u00a0performance against treatment drivers and goals.<\/li>\n<li>Physicians\u2019 perception\u00a0of unmet need in this disease and related indications.<\/li>\n<li>Analysis of remaining drug development opportunities.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390516","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390516\/revisions"}],"predecessor-version":[{"id":393640,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390516\/revisions\/393640"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}